Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Revance Therapeutics, Inc. | Director | Common Stock | 43.6K | $166K | $3.80 | May 1, 2024 | Direct |
POLARITYTE, INC. | Director | Common Stock | 14.4K | $11.4K | $0.79 | Jan 12, 2023 | Direct |
Revance Therapeutics, Inc. | Director | Stock Option (Right to buy) | 23.5K | May 1, 2024 | Direct | ||
ArriVent Biopharma, Inc. | Director | Stock Option (right to buy) | 17.9K | Jan 25, 2024 | Direct | ||
Jasper Therapeutics, Inc. | Director | Stock Option (right to buy) | 7.5K | Jun 6, 2024 | Direct | ||
POLARITYTE, INC. | Director | Stock option (right to buy) | 6.16K | Jan 12, 2023 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
JSPR | Jasper Therapeutics, Inc. | Jun 6, 2024 | 1 | $0 | 4 | Jun 10, 2024 | Director |
RVNC | Revance Therapeutics, Inc. | May 1, 2024 | 2 | $0 | 4 | May 3, 2024 | Director |
AVBP | ArriVent Biopharma, Inc. | Jan 25, 2024 | 1 | $0 | 4 | Jan 29, 2024 | Director |
AVBP | ArriVent Biopharma, Inc. | Jan 25, 2024 | 0 | $0 | 3 | Jan 25, 2024 | Director |
JSPR | Jasper Therapeutics, Inc. | Jun 7, 2023 | 1 | $0 | 4 | Jun 8, 2023 | Director |
RVNC | Revance Therapeutics, Inc. | May 3, 2023 | 2 | $0 | 4 | May 5, 2023 | Director |
PTE | POLARITYTE, INC. | Jan 12, 2023 | 2 | $0 | 4 | Jan 17, 2023 | Director |
JSPR | Jasper Therapeutics, Inc. | Oct 12, 2022 | 1 | $0 | 4 | Oct 13, 2022 | Director |
PTE | POLARITYTE, INC. | Oct 1, 2022 | 1 | $0 | 4 | Oct 4, 2022 | Director |
RVNC | Revance Therapeutics, Inc. | May 4, 2022 | 1 | $0 | 4/A | May 13, 2022 | Director |
JSPR | Jasper Therapeutics, Inc. | Mar 21, 2022 | 1 | $0 | 4 | Mar 23, 2022 | Director |
JSPR | Jasper Therapeutics, Inc. | Sep 24, 2021 | 0 | $0 | 3 | Oct 1, 2021 | Director |
RVNC | Revance Therapeutics, Inc. | May 5, 2021 | 2 | $0 | 4 | May 7, 2021 | Director |